Exenatide - Intarcia Therapeutics/IQVIA/Servier
Alternative Names: Exenatide in DUROS®; Exenatide intravenous - Intarcia Therapeutics/IQVIA/Servier; Exenatide subcutaneous implant - Intarcia Therapeutics/IQVIA/Servier; Exendin-4; ITCA-650Latest Information Update: 05 Nov 2023
At a glance
- Originator Intarcia Therapeutics
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2023 i2o Therapeutics acquires Exenatide from Intarcia Therapeutics
- 03 Sep 2021 No development reported - Phase-III for Type 2 diabetes mellitus (Adjunctive treatment) in Netherlands, Canada, Sweden, Turkey, Czech Republic, South Africa, Slovakia, Romania, Croatia, Poland, Spain, Bulgaria, Germany, Finland, Estonia, Hungary, Latvia, Denmark (SC)
- 08 Oct 2019 Intarcia resubmits NDA to US FDA for Type 2 diabetes mellitus